Alaunos Therapeutics (TCRT) Competitors

Alaunos Therapeutics logo
$1.60 -0.03 (-1.84%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.58 -0.02 (-1.25%)
As of 11/16/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TCRT vs. ATOS, CNTX, KTTA, ATYR, and AKTX

Should you buy Alaunos Therapeutics stock or one of its competitors? Alaunos Therapeutics's main competitors and comparable companies include Atossa Genetics (ATOS), Context Therapeutics (CNTX), Pasithea Therapeutics (KTTA), aTyr Pharma (ATYR), and Akari Therapeutics (AKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alaunos Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Atossa Genetics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, suggesting that its share price is 202% less volatile than the broader market.

In the previous week, Atossa Genetics and Atossa Genetics both had 4 articles in the media. Atossa Genetics' average media sentiment score of 1.20 beat Alaunos Therapeutics' score of 0.94 indicating that Atossa Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atossa Genetics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alaunos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Atossa Genetics' return on equity of -117.07% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -117.07% -96.08%
Alaunos Therapeutics N/A -232.60%-158.99%

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 943.81%. Given Atossa Genetics' stronger consensus rating and higher probable upside, research analysts clearly believe Atossa Genetics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.11N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

Summary

Atossa Genetics beats Alaunos Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Context Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Context Therapeutics had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 6 mentions for Context Therapeutics and 4 mentions for Alaunos Therapeutics. Context Therapeutics' average media sentiment score of 1.14 beat Alaunos Therapeutics' score of 0.94 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alaunos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Context Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Context Therapeutics' return on equity of -96.54% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -232.60% -158.99%
Context Therapeutics N/A -96.54%-83.59%

Alaunos Therapeutics has a beta of -1.02, meaning that its share price is 202% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Context Therapeutics has a consensus target price of $6.40, indicating a potential upside of 3,757.75%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Context Therapeutics
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A
Context TherapeuticsN/AN/A-$36.12M-$0.46N/A

Summary

Context Therapeutics beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Pasithea Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Pasithea Therapeutics' return on equity of -49.49% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -232.60% -158.99%
Pasithea Therapeutics N/A -49.49%-46.81%

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A

Alaunos Therapeutics has a beta of -1.02, meaning that its share price is 202% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

In the previous week, Pasithea Therapeutics had 4 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 8 mentions for Pasithea Therapeutics and 4 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.94 beat Pasithea Therapeutics' score of 0.64 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alaunos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pasithea Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 500.00%. Given Pasithea Therapeutics' higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Pasithea Therapeutics beats Alaunos Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Alaunos Therapeutics compare to aTyr Pharma?

Alaunos Therapeutics (NASDAQ:TCRT) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

aTyr Pharma has a consensus price target of $5.00, indicating a potential downside of 4.58%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

Alaunos Therapeutics has higher earnings, but lower revenue than aTyr Pharma. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A
aTyr Pharma$190K70.33-$74.12M-$21.83N/A

In the previous week, aTyr Pharma had 7 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 11 mentions for aTyr Pharma and 4 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.94 beat aTyr Pharma's score of 0.20 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alaunos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 5.0% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

aTyr Pharma's return on equity of -102.83% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -232.60% -158.99%
aTyr Pharma N/A -102.83%-70.56%

Alaunos Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Summary

aTyr Pharma beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Akari Therapeutics had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 5 mentions for Akari Therapeutics and 4 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.94 beat Akari Therapeutics' score of 0.30 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alaunos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Akari Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the broader market.

Akari Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 396.67%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Akari Therapeutics' return on equity of -143.89% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -143.89% -73.26%
Alaunos Therapeutics N/A -232.60%-158.99%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 30.0% of Akari Therapeutics shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Akari Therapeutics beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRT vs. The Competition

MetricAlaunos TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.37M$4.15B$7.83B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5633.3627.60
Price / SalesN/A16.048.595.73
Price / CashN/A26.3721.9322.50
Price / Book1.724.074.403.70
Net Income-$4.18M-$22.86M$3.52B$392.17M
7 Day Performance-6.43%-6.15%-4.48%-3.37%
1 Month Performance-39.16%-4.92%-3.53%-5.82%
1 Year Performance-50.31%-3.09%0.12%-6.24%

Alaunos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
1.3044 of 5 stars
$1.60
-1.8%
N/A-46.1%$5.37MN/AN/A1
ATOS
Atossa Genetics
3.1739 of 5 stars
$1.94
-4.4%
$20.33
+948.1%
-83.8%$20.26MN/AN/A14
CNTX
Context Therapeutics
3.0155 of 5 stars
$0.20
-8.4%
$6.40
+3,132.3%
-85.7%$19.85MN/AN/A15
KTTA
Pasithea Therapeutics
2.6084 of 5 stars
$0.52
-2.3%
$3.00
+477.0%
-30.4%$17.78MN/AN/A5
ATYR
aTyr Pharma
1.792 of 5 stars
$6.21
-8.3%
$5.00
-19.5%
-82.6%$17.26M$190KN/A58

Related Companies and Tools


This page (NASDAQ:TCRT) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners